Thymogen
Aliases: Timogen · Glu-Trp
Last verified: 2026-09-23
The short version
A dipeptide (Glu-Trp) — a Russian immunomodulator approved for secondary immunodeficiencies; the "minimal" thymic bioregulator. Key fact: Russian trials in immunodeficiency and infections.
Identity & type
- Molecular type
- bioregulator
- Origin
- A dipeptide (Glu-Trp) — a Russian immunomodulator approved for secondary immunodeficiencies; the "minimal" thymic bioregulator.
Mechanism of action
Regulates T-cell differentiation and NK activity; cyclic-nucleotide pathways.
not confirmed in humans
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. 100 mcg IM daily for 3–10 days or nasally.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
100 mcg IM daily for 3–10 days or nasally. A dipeptide immunomodulator: Russian experience — fewer infections in the immunodeficient; the Western community barely knows it.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
A dipeptide immunomodulator: Russian experience — fewer infections in the immunodeficient; the Western community barely knows it.
Protocol — official vs community
Official / label
100 mcg IM daily for 3–10 days; an intranasal formulation is dosed at 100 mcg daily in Russian protocols.
- 01100 mcg IM or intranasal daily, 3–10 days
Duration: Short course-based immunomodulation; repeat per treating protocol.
Approved in Russia as the Glu-Trp dipeptide for secondary immunodeficiencies. One of the few Khavinson-school compounds with an actual drug registration.
Community (anecdotal)
Mirrors the Russian protocol: 100 mcg IM or intranasal daily for 3–10 days.
- Cycle:
- Short courses around immune stressors or seasons, per community practice.
- Break:
- Courses are short by design; no chronic-use pattern.
At microgram doses Thymogen is the least speculative member of the class — the label is the protocol.
Human evidence
Russian trials in immunodeficiency and infections.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Very rare reactions.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics